Weight-loss drugs sharpen focus on preserving muscle in later life

As sarcopenia threatens mobility and independence with age, doctors are urging people using GLP-1 medicines to combine weight loss with protein, resistance training and muscle monitoring.

Sarcopenia is the gradual loss of muscle mass, strength and physical function that often begins after the age of 60 and becomes more pronounced with time. As muscle tissue declines, people may feel less energetic, move less easily and become more vulnerable to falls and fractures, with knock-on effects on independence and quality of life. Cleveland Clinic describes it as an age-related condition that affects both muscle quantity and performance, while Harvard Health says it becomes increasingly common in later life, especially among older adults with poor nutrition or limited activity.

The condition matters because skeletal muscle does far more than power movement. According to the Metropolitan Hospital specialists quoted in Documentonews.gr, muscle also supports breathing, heat production and metabolic balance through the release of myokines, signalling molecules that help regulate glucose use, fat metabolism and liver function. When people become inactive, those benefits diminish, which helps explain why sedentary living is so often linked with cardiometabolic disease.

Doctors can now measure muscle loss with far greater precision than in the past. The Greek article notes that body composition can be assessed with DEXA scanning, CT or MRI, as well as bioelectrical impedance analysis, which is widely used because it is simpler and less invasive. Functional tests such as grip strength, walking speed, the chair-stand test and the six-minute walk test are also important, because muscle mass alone does not tell the full story; what matters is whether the muscles still work well enough for everyday life.

Ageing is not the only driver. The article points to hormonal changes, chronic inflammation, nerve and muscle decline, and nutritional shortfalls such as anaemia, low protein intake and deficiencies in vitamin D or vitamin B12. Cleveland Clinic and Harvard Health likewise link sarcopenia to inactivity, malnutrition and other underlying health problems. The practical signs are often familiar: weaker legs, slower walking, less stamina, difficulty rising from a chair, and a growing risk of injury from falls.

The discussion has taken on new urgency as weight-loss medicines become more common. The Metropolitan Hospital doctors cited by Documentonews.gr say that GLP-1 medicines, including liraglutide, semaglutide and tirzepatide, can produce substantial weight loss but may also be accompanied by some loss of lean tissue. Their account suggests the pattern varies by drug: semaglutide has been associated with significant weight reduction alongside a notable share of muscle loss, liraglutide with more moderate loss, and tirzepatide with large overall weight reduction and a somewhat lower proportion of muscle loss. While these medicines remain valuable for obesity and type 2 diabetes, the concern is that rapid weight loss without muscle preservation may increase frailty unless it is properly managed.

Prevention and treatment therefore centre on two familiar pillars: nutrition and exercise. The Greek article recommends higher protein intake for older adults, particularly those with low muscle mass, along with protein-rich foods, vitamin D, antioxidant-rich fruit and vegetables, and, where appropriate, supplements such as creatine or L-leucine. It also advises resistance training several times a week and regular aerobic exercise. NIH News in Health, Harvard Health and Cleveland Clinic all reach the same broad conclusion: early intervention, adequate protein and strength training are the most reliable ways to slow muscle loss and preserve mobility. For people using weight-loss medicines, the article argues that periodic monitoring of muscle mass should become part of routine care, so treatment reduces fat without eroding the muscle needed for autonomy and healthy ageing.